Institute for Applied Health Research, Glasgow Caledonian University, Glasgow, Scotland.
J Am Med Dir Assoc. 2013 Apr;14(4):270-4. doi: 10.1016/j.jamda.2012.10.021. Epub 2012 Nov 30.
To assess preliminary effects of a program of transcutaneous posterior tibial nerve stimulation (TPTNS) on lower urinary tract symptoms and number of episodes of urinary and fecal incontinence in older adults in residential care homes and the feasibility of a full-scale randomized trial.
Pilot randomized single-blind, placebo-controlled trial.
Seven residential care homes and 3 sheltered accommodation complexes in the United Kingdom.
Thirty care home residents aged 65 and older with urinary or bowel symptoms and/or incontinence.
Twelve 30-minute sessions of TPTNS or sham stimulation (placebo).
Lower urinary tract symptoms using American Urological Society Symptom Index, urinary incontinence using International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), postvoid residual urine volumes using portable bladder scanning, bowel symptoms and fecal incontinence using selected ICIQ questions.
Total American Urological Society Symptom Index scores improved, showing a median reduction of 7 (interquartile range [IQR] -8 to -3) in the TPTNS group and a median increase in the sham stimulation (placebo) group of 1 (IQR -1 to 4) (Mann-Whitney U 16.5000, Z -3.742, P < .001). Total ICIQ-SF scores improved by a median of 2 (IQR -6 to 0) in the TPTNS group and 0 points (IQR -3 to 3) in the sham stimulation group (Mann-Whitney U 65.000, Z -1.508, P = .132). Significant reduction was found in postvoid residual urine of 55 mL in the TPTNS group (t = -2.215, df 11.338, P = .048). Bowel urgency improved in 27% of the TPTNS group compared with 8% of the sham group (χ(2) 2.395, df 2, P > .302), fecal leakage improved in 47% of the TPTNS group compared with 23% of the sham group (χ(2) 4.480, df 2, P > .106); however, these differences were not significant. No adverse effects were reported by older adults or care staff.
TPTNS is safe and acceptable with evidence of potential benefit for bladder and bowel dysfunction in older male and female residents of care homes. Data support the feasibility of a substantive trial of TPTNS in this population.
评估经皮胫后神经刺激(TPTNS)方案对老年居住在养老院中的下尿路症状和尿失禁及粪便失禁发作次数的初步影响,并评估一项全面的随机试验的可行性。
初步随机单盲、安慰剂对照试验。
英国的 7 家养老院和 3 家庇护住所。
30 名年龄在 65 岁及以上的有尿路或肠道症状和/或失禁的养老院居民。
12 次 30 分钟的 TPTNS 或假刺激(安慰剂)。
采用美国泌尿外科学会症状指数评估下尿路症状,采用国际尿失禁咨询问卷-短表(ICIQ-SF)评估尿失禁,采用便携式膀胱扫描评估残余尿量,采用 ICIQ 选定问题评估肠道症状和粪便失禁。
总的美国泌尿外科学会症状指数评分有所改善,TPTNS 组的中位数降低了 7 分(四分位距 [IQR] -8 至 -3),而假刺激(安慰剂)组的中位数增加了 1 分(IQR -1 至 4)(Mann-Whitney U 16.5000,Z -3.742,P <.001)。TPTNS 组的 ICIQ-SF 总分中位数改善了 2 分(IQR -6 至 0),而假刺激组则改善了 0 分(IQR -3 至 3)(Mann-Whitney U 65.000,Z -1.508,P =.132)。TPTNS 组的残余尿量减少了 55 毫升(t = -2.215,df 11.338,P =.048)。TPTNS 组中 27%的患者肠道急迫感得到改善,而假刺激组中只有 8%的患者(χ(2) 2.395,df 2,P >.302);TPTNS 组中 47%的患者粪便渗漏得到改善,而假刺激组中只有 23%的患者(χ(2) 4.480,df 2,P >.106);然而,这些差异没有统计学意义。老年人或护理人员均未报告任何不良反应。
TPTNS 是安全且可接受的,对养老院中男性和女性老年居民的膀胱和肠道功能障碍有潜在益处。数据支持在这一人群中进行 TPTNS 实质性试验的可行性。